Profectus BioSciences Inc. is launching the first phase of an HIV vaccine study alongside an international panel of scientists researching the disease.
The study is testing 60 HIV-negative adults using a “recombinant” version of the virus that has been weakened so it doesn’t cause illness in animals or humans. It will look at the safety and effectiveness of increasing doses of a vaccine that contains a protein designed to block the virus from infecting humans.
Baltimore-based Profectus is working with the HIV Vaccine Trials Network on the study, which is also being sponsored by the National Institutes of Allergy and Infectious Diseases.
Read More
The study is testing 60 HIV-negative adults using a “recombinant” version of the virus that has been weakened so it doesn’t cause illness in animals or humans. It will look at the safety and effectiveness of increasing doses of a vaccine that contains a protein designed to block the virus from infecting humans.
Baltimore-based Profectus is working with the HIV Vaccine Trials Network on the study, which is also being sponsored by the National Institutes of Allergy and Infectious Diseases.
Read More
No comments:
Post a Comment